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Abstract 
Neuraminidase-1 (NEU1) is the predominant sialidase expressed in human airway epithelia and 
lung microvascular endothelia where it mediates multiple biological processes. We tested 
whether the NEU1-selective sialidase inhibitor, C9-butyl-amide-2-deoxy-2,3-dehydro-N-
acetylneuraminic acid (C9-BA-DANA), inhibits one or more established NEU1-mediated 
bioactivities in human lung cells. We established the IC50 values of C9-BA-DANA for total 
sialidase activity in human airway epithelia, lung microvascular endothelia and lung fibroblasts 
to be 3.74 µM, 13.0 µM and 4.82 µM, respectively. In human airway epithelia, C9-BA-DANA 
dose-dependently inhibited flagellin-induced, NEU1-mediated mucin-1 ectodomain 
desialylation, adhesiveness for Pseudomonas aeruginosa and shedding. In lung microvascular 
endothelia, C9-BA-DANA reversed NEU1-driven restraint of cell migration into a wound and 
disruption of capillary-like tube formation. NEU1 and its chaperone/transport protein, protective 
protein/cathepsin A (PPCA), were differentially expressed in these same cells. Normalized 
NEU1 protein expression correlated with total sialidase activity whereas PPCA expression did 
not. In contrast to eukaryotic sialidases, C9-BA-DANA exerted far less inhibitory activity for 
three selected bacterial neuraminidases (IC50 > 800 µM). Structural modeling of the four human 
sialidases and three bacterial neuraminidases revealed a loop between the seventh and eighth 
strands of the β-propeller fold, that in NEU1, was substantially shorter than that seen in the six 
other enzymes. Predicted steric hindrance between this loop and C9-BA-DANA could explain its 
selectivity for NEU1. Finally, pretreatment of mice with C9-BA-DANA completely protected 
against flagellin-induced increases in lung sialidase activity. Our combined data indicate that C9-
BA-DANA inhibits endogenous and ectopically expressed sialidase activity and established 
NEU1-mediated bioactivities in human airway epithelia, lung microvascular endothelia, and 
fibroblasts in vitro and murine lungs in vivo. 
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Introduction 
The surface of all eukaryotic cells is sialylated (Varki and Varki 2007; Cohen and Varki 2010). 
Glycoproteins and glycolipids expressed on the cell surface contain oligosaccharide chains 
whose outermost positions can terminate with sialic acid. The sialylation state of these surface 
structures is regulated, at least in part, through sialidase catalytic activity (Monti et al. 2002; 
Monti et al. 2010; Miyagi and Yamaguchi 2012). At least four human sialidases, also referred to 
as neuraminidases, have been identified, NEU1, -2, -3 and -4 (Pshezhetsky et al. 1997; Miyagi et 
al. 1999; Monti et al. 1999; Comelli et al. 2003). Superimposed on this complex biological 
system, the human host also intimately interacts with numerous microbes that express their own 
neuraminidases (Kim et al. 2011; Lewis and Lewis 2012). Whether eukaryotic sialidases 
participate in specific biological processes is only now being explored and remains incompletely 
understood. Sialidases reportedly influence growth factor and Toll-like receptor (TLR) 
responsiveness and signaling (Hinek et al. 2008; Amith et al. 2009, 2010; Abdulkhalek et al. 
2011, 2012; Feng et al. 2012; Lillehoj et al. 2012; Abdulkhalek and Szewczuk 2013), insulin 
receptor activation and downstream signaling (Arabkhari et al. 2010; Dridi et al. 2013), elastin 
fiber assembly (Hinek et al. 2006; Duca et al. 2007; Starcher et al. 2008), neuronal and muscle 
cell differentiation (Fanzani et al. 2003; Kappagantula et al. 2014), angiogenesis (Lee et al. 
2014), tumor cell biology and cancer metastasis (Miyagi et al. 2004, 2008; Uemura et al. 2009), 
sperm function during fertilization (Ma et al. 2012) and bacterial pathogenesis (Chen et al. 2011; 
Lillehoj et al. 2012). Our research group has focused on sialidase biology in three key cell types 
within the human lung, i.e. airway epithelia (Lillehoj et al. 2012, 2015), microvascular 
endothelia (Cross et al. 2012; Lee et al. 2014) and fibroblasts (Luzina et al. 2016). First, we 
found that NEU1 was the predominant sialidase expressed in human airway epithelia, lung 
microvascular endothelia and lung fibroblasts (Cross et al. 2012; Lillehoj et al. 2012; Luzina et 
al. 2016). In human airway epithelial cells (HAECs), NEU1 impaired the migratory response 
during wound repair (Luzina et al. 2016). In these same cells, we previously established 
Pseudomonas aeruginosa (Pa)-derived flagellin as a signal-transducing ligand for 
the ectodomain of mucin-1 (MUC1-ED) (Lillehoj et al. 2012, 2015), and more recently, found 
that flagellin stimulation increases NEU1 association with and desialylation of the MUC1-ED 
(Lillehoj et al. 2015). NEU1-mediated MUC1-ED desialylation increased both its adhesiveness 
for flagellin-expressing Pa and its shedding from the HAEC surface (Lillehoj et al. 2015). In 
human pulmonary microvascular endothelial cell (HPMEC)s, we found that NEU1 restrained 
HPMEC migration into a wound (Cross et al. 2012; Lee et al. 2014) and disrupted HPMEC 
capillary-like tube formation, i.e. in vitro angiogenesis (Lee et al. 2014). More recently, we 
found that NEU1 expression is increased in lung tissues of patients with idiopathic pulmonary 
fibrosis (IPF) (Luzina et al. 2016). In these reports, the impact of NEU1 on any specific cellular 
response was established through prior siRNA-induced silencing of NEU1 and NEU1 
overexpression (Cross et al. 2012; Lillehoj et al. 2012, 2015; Lee et al. 2014; Luzina et al. 2016). 
However, such interventions would not be easily applied to human disease states in vivo. 
NEU1 participates in multiple cellular functions (Monti et al. 2002, 2010; Miyagi and 
Yamaguchi 2012). In most human cells, NEU1 is co-expressed with NEU2, -3 and -4 (Monti et 
al. 2002, 2010; Miyagi and Yamaguchi 2012). Selective inhibition of NEU1 without off-target 
cross-inhibition of any of the other three isoforms could provide insight into NEU1 function 
and/or therapeutic possibilities for clinical conditions in which NEU1 might be overexpressed 
and/or activated. Furthermore, NEU1-null mice display lung pathology and premature death, 
thereby limiting studies of NEU1 function (Starcher et al. 2008). Most previous studies of 
neuraminidase/sialidase inhibition have utilized recombinant enzymes in cell-free experimental 
systems (Hata et al. 2008; Magesh et al. 2008, 2009; Zhang et al. 2013). In the current studies, 
we tested the ability of the only reported NEU1-selective inhibitor, C9-butyl-amide-2-deoxy-2,3-
dehydro-N-acetylneuraminic acid (C9-BA-DANA) (Magesh et al. 2008), to inhibit NEU1-
mediated biological processes in both in vitro cell culture systems and in an intact murine model. 
Although the overall sequence identities between individual members of the 
neuraminidase/sialidase superfamily are low, each contains several conserved motifs and their 
catalytic domains share a common six-bladed β-propeller fold architecture (Monti et al. 2002; 
Miyagi and Yamaguchi 2012). Of the four known human sialidases, the crystal structure of only 
NEU2 has been solved (Chavas et al. 2005). Several research groups have now designed and 
synthesized pharmacologic inhibitors selective for both prokaryotic neuraminidases (von Itzstein, 
2007) and eukaryotic sialidases (Magesh et al. 2006, 2008, 2009; Zhang et al. 2013). One 
standard inhibitor, 2-deoxy-2,3-dehydro-N-acetylneuraminic acid (DANA), is a broad spectrum, 
transition state analog inhibitor of viral, bacterial and mammalian neuraminidases/sialidases 
(Meindi and Tuppy 1969; Burmeister et al. 1993). We designed and synthesized a series of 10 N-
amide-linked C9-modified analogs of DANA and tested their inhibitory activities against all four 
human sialidases (Magesh et al. 2008). We found that the C9 N-amide-linked n-butyl derivative 
of DANA, C9-BA-DANA, displayed ~15-fold increased inhibitory activity for NEU1 and >100-
fold decreased inhibitory activity for NEU2, -3 and -4 compared to that seen with unmodified 
DANA. When C9-BA-DANA was tested against each human sialidase expressed in HEK-293 
cells, it was >200-fold more selective for NEU1 (IC50 = 10 µM) versus NEU2, -3 and -4 
(IC50 > 1000 µM). Whether C9-BA-DANA might inhibit bacterial neuraminidases has not been 
tested. In the current studies, we have tested whether C9-BA-DANA might block endogenous 
and/or ectopically expressed sialidase activity in human airway epithelia, lung microvascular 
endothelia and/or lung fibroblasts, and inhibit established NEU1-driven biological processes in 
two of these same three cell systems. The inhibitory activity for C9-BA-DANA against 




C9-BA-DANA inhibits sialidase activity in HAECs 
We previously established NEU1 as the predominant sialidase expressed in HAECs (Lillehoj et 
al. 2012) and defined its participation in multiple bioactivities in these same cells (Lillehoj et al. 
2012, 2015; Luzina et al. 2016). To better control NEU1-mediated events in the airway 
epithelium, we asked whether the NEU1-selective inhibitor, C9-BA-DANA (Magesh et al. 
2008), might inhibit sialidase activity in A549 cells. A fixed amount of A549 cellular protein or a 
fixed number of A549 cells were assayed for sialidase activity for the fluorogenic substrate, 2′-
(4-methylumbelliferyl)-α-d-N-acetylneuraminic acid (4-MU-NANA), in the presence of 
increasing concentrations of C9-BA-DANA (Figure (Figure1A).1A). C9-BA-DANA, at 
concentrations ≥1.34 µM, dose-dependently inhibited A549 cell sialidase activity with an IC50 of 




Fig. 1.  C9-BA-DANA inhibits sialidase activity and flagellin-stimulated, NEU1-mediated 
MUC1-ED desialylation, increases in adhesiveness for Pa, and shedding in HAECs. (A) A fixed 
amount of A549 cellular protein (0.63 mg) or a fixed number of A549 cells (106 cells/reaction) 
were assayed for sialidase activity for the fluorogenic substrate, 4-MU-NANA, in the presence of 
increasing concentrations of C9-BA-DANA. Vertical bars represent mean (±SE) sialidase 
activity expressed as arbitrary fluorescence units/mg protein (left Y-axis) or arbitrary 
fluorescence units/106 cells (right Y-axis) (n = 2/4). *, decreased sialidase activity in the presence 
versus absence of C9-BA-DANA at P < 0.05. (B) The positive control asialofetuin and the 
negative control fetuin (1.0 µg of each) were processed for PNA lectin blotting. IB, immunoblot. 
Molecular weight in kDa indicated on the left. (C-F) A549 cells were incubated for 30 min (C–
E) or 24 h (F) with 10 ng/mL of Pa flagellin or medium alone in the presence of increasing 
concentrations of C9-BA-DANA (C–F) or 100 μM of DANA (F). (C) The cells were lysed and 
the lysates were incubated with PNA-agarose and the PNA-binding proteins processed for 
MUC1-ED immunoblotting. PD, pull-down; IB, immunoblot. Molecular weight in kDa indicated 
on the left. (D) Densitometric analyses of the blots in (C). Vertical bars represent mean (±SE) 
PNA-bound MUC1-ED signal (n = 3). *, increased MUC1-ED desialylation in flagellin-treated 
versus untreated cells at P < 0.05. **, decreased MUC1-ED desialylation in C9-BA-DANA 
treated versus untreated cells at P < 0.05. (E) The cells were fixed, washed and incubated for 30 
min with Pa (MOI = 100). Nonadherent Pa was removed by washing, and CFUs of cell-bound Pa 
quantified. Vertical bars represent mean (±SE) Pa CFUs/well (n = 9). *, increased Pa adhesion to 
flagellin-treated versus untreated cells at P < 0.05. **, decreased Pa adhesion to C9-BA-DANA 
treated versus untreated cells at P < 0.05. (F) The cells were cultured for 24 h after which 
MUC1-ED levels in supernates were quantified by ELISA and normalized to total cellular 
protein. Vertical bars represent mean (±SE) shed MUC1-ED normalized to total cellular protein 
(n = 3/12). *, increased shed MUC1-ED in supernates of flagellin-treated versus untreated cells 
at P < 0.05. **, decreased shed MUC1-ED in supernates in C9-BA-DANA treated 
versus untreated cells at P < 0.05. (G) A549 cells were cultured for 24 h in the presence of 100 
µM of C9-BA-DANA or medium alone after which MTT was added for an additional 4 h. After 
DMSO solubilization, the A490 was measured. Vertical bars represent the mean (±SE) A490 
(n = 3). Each result is representative of ≥3 independent experiments. 
 
 
C9-BA-DANA inhibits flagellin-stimulated, NEU1-mediated MUC1-ED 
desialylation, increases in adhesiveness for Pa, and shedding 
We previously demonstrated that Pa-derived flagellin is a ligand for the MUC1-ED (Lillehoj et 
al. 2012, 2015) and that its engagement of this receptor increases NEU1 association with and 
desialylation of MUC1-ED (Lillehoj et al. 2015). Furthermore, NEU1-mediated desialylation of 
MUC1-ED renders it hyperadhesive for Pa and increases its shedding from the cell surface 
(Lillehoj et al. 2015). First, we asked whether C9-BA-DANA could inhibit MUC1-ED 
desialylation as measured by quantitative peanut agglutinin (PNA) lectin blotting. The PNA 
lectin probe was validated using asialofetuin and fetuin as nonsialylated positive and sialylated 
negative controls, respectively (Figure (Figure1B).1B). As anticipated, PNA recognized 
asialofetuin (lane 2) but not fetuin (lane 1). Flagellin increased PNA recognition of MUC1-ED 
by 2.2-fold and C9-BA-DANA at concentrations ≥10 µM dose-dependently protected against 
this desialylation (Figure (Figure1C,D).1C,D). Although C9-BA-DANA at 1.0 µM diminished 
MUC1-ED desialylation, this decrease did not achieve statistical significance (P = 0.16) (Figure 
(Figure1D).1D). C9-BA-DANA at 100 µM completely reversed the flagellin-induced MUC1-ED 
desialylation. Since C9-BA-DANA clearly inhibited MUC1-ED desialylation, we asked whether 
it might also diminish flagellin-induced increases in Pa adhesion to MUC1-ED-expressing cells 
(Figure (Figure1E)1E) and/or MUC1-ED shedding (Figure (Figure1F).1F). As anticipated, 
flagellin increased Pa adhesion by 3.5-fold, and again, C9-BA-DANA at concentrations ≥10 µM 
dose-dependently protected against increases in Pa adhesion with almost complete reversal at 
100 µM (Figure (Figure1E).1E). Similarly, flagellin increased MUC1-ED shedding 3.2-fold and 
C9-BA-DANA at concentrations ≥10 µM dose-dependently decreased shedding (Figure 
(Figure1F).1F). However, C9-BA-DANA at 100 µM only diminished flagellin-provoked 
shedding by 46.8% (Figure (Figure1F).1F). We asked whether the more broad spectrum, less 
specific sialidase inhibitor, DANA, might more effectively decrease MUC1-ED shedding 
through its ability to target sialidase(s) other than NEU1. DANA, at an equivalent concentration, 
inhibited shedding by 52.7%, comparable to the inhibition seen with the more NEU1-selective 
inhibitor, C9-BA-DANA (Figure (Figure1F).1F). No difference in viability was detected 
between A549 cells cultured for 24 h in the presence of 100 µM of C9-BA-DANA or medium 
alone (Figure (Figure1G),1G), indicating that none of the above results could be ascribed to 
cytotoxic effects of the compound. These combined data indicate that C9-BA-DANA dose-
dependently protected versus flagellin-stimulated MUC1-ED desialylation, which in turn, 
counter-regulated increases in both Pa adhesion and MUC1-ED shedding. 
C9-BA-DANA inhibits sialidase activity in HPMECs 
We previously found NEU1 to be the predominant sialidase expressed in HPMECs (Cross et al. 
2012). We asked whether C9-BA-DANA might inhibit HPMEC sialidase activity. A fixed 
amount of HPMEC protein or a fixed number of HPMECs were assayed for sialidase activity in 
the 4-MU-NANA assay in the presence of increasing concentrations of C9-BA-DANA (Figure 
(Figure2A).2A). C9-BA-DANA, at concentrations ≥2.67 µM, dose-dependently inhibited 




Fig. 2. C9-BA-DANA inhibits sialidase activity and counteracts NEU1-mediated inhibition of 
HPMEC migration and capillary-like tube formation. (A) A fixed amount of HPMEC protein 
(0.71 mg) or a fixed number of HPMECs (106 cells/reaction) were assayed for sialidase activity 
for 4-MU-NANA in the presence of increasing concentrations of C9-BA-DANA. Vertical bars 
represent mean (±SE) sialidase activity expressed as arbitrary fluorescence units/mg protein (left 
Y-axis) or arbitrary fluorescence units/106 cells (right Y-axis) (n = 2/4). *, decreased sialidase 
activity in the presence versus absence of C9-BA-DANA at P < 0.05. (B–E) HPMECs and 
HPMECs infected with Ad-NEU1 or Ad-GFP (MOI = 100) were cultured for 48 h. (B, C) A 
single wound was made across the diameter of each confluent monolayer, after which the 
wounded monolayers were incubated for 24 h in the absence or presence of 134 µM of C9-BA-
DANA and photomicrographs taken. (C) The number of migrating HPMECs was calculated 
using ImageJ software for comparison with that observed in the same wounded monolayer at 0 h, 
as a measure of migration into the wound. Each vertical bar represents mean (±SE) migration 
into the wound (n = 3/5). *, decreased migration in Ad-NEU1 infected versus Ad-GFP infected 
cells at P < 0.05. **, increased migration in C9-BA-DANA treated, Ad-NEU1 infected vs. 
untreated, Ad-NEU1 infected cells at P < 0.05. (D) HPMECs were seeded on Matrigel-coated 
wells at 1.5 × 104 cells/well, and after 6 h, tubular structures photographed. (E) Segments of 
capillary-like tubes per HPF were counted. Vertical bars represent mean (±SE) segments/HPF 
(n = 7). *, decreased tube formation in Ad-NEU1 infected versus Ad-GFP infected cells at P 
< 0.05. **, increased tube formation in C9-BA-DANA treated, Ad-NEU1 infected versus 
untreated, Ad-NEU1 infected cells at P < 0.05. (F) HPMECs were cultured for 24 h in the 
presence of 100 µM of C9-BA-DANA or medium alone after which MTT was added for an 
additional 4 h. After DMSO solubilization, the A490 was measured. Vertical bars represent mean 
(±SE) A490 (n = 3). Each result is representative of ≥3 independent experiments. This figure is 
available in black and white in print and in color at Glycobiology online. 
 
C9-BA-DANA counteracts NEU1-mediated inhibition of HPMEC migration and 
capillary-like tube formation 
We previously reported that NEU1 overexpression in HPMECs restrains their migration into a 
wound (Cross et al. 2012; Lee et al. 2014) and disrupts in vitro angiogenesis (Lee et al. 2014). 
HPMECs and HPMECs infected with adenovirus (Ad) encoding human NEU1 (Ad-NEU1) or 
green fluorescent protein (Ad-GFP) as a control, were studied in the presence or absence of C9-
BA-DANA, for migration in wounding assays (Figure (Figure2B,C)2B,C) and capillary-like tube 
formation on Matrigel (Figure (Figure2D,E).2D,E). In the uninfected HPMECs, C9-BA-DANA 
did not alter cell migration compared to simultaneous medium controls (Figure 
(Figure2B,C).2B,C). NEU1 overexpression diminished HPMEC migration into a wound by 
58.6% and the presence of C9-BA-DANA reversed the NEU1-driven inhibition by 84.2% 
(Figure (Figure2B,C).2B,C). Similarly, NEU1 overexpression decreased capillary-like tube 
formation by 39.7% and C9-BA-DANA reversed the NEU1-mediated inhibition by 70.0% 
(Figure (Figure2D,E).2D,E). No difference in viability was detected between HPMECs cultured 
for 24 h in the presence of 100 µM of C9-BA-DANA or medium alone (Figure (Figure2F).2F). 
These combined data indicate that C9-BA-DANA protects against NEU1-mediated inhibition of 
both the HPMEC migratory response to injury and capillary-like tube formation or in vitro 
angiogenesis. 
C9-BA-DANA inhibits sialidase activity in HLFs 
We recently reported that human lung fibroblasts (HLFs) express NEU1, and NEU1 expression 
is increased in fibroblasts obtained from the lungs of IPF patients (Luzina et al. 2016). To test 
whether C9-BA-DANA inhibits sialidase activity in HLFs, a fixed amount of HLF protein or a 
fixed number of HLFs were assayed for sialidase activity for the fluorogenic substrate, 4-MU-
NANA, in the presence of increasing concentrations of C9-BA-DANA (Figure (Figure3A).3A). 
C9-BA-DANA, at concentrations ≥1.34 µM, dose-dependently inhibited HLF sialidase activity 
with an IC50 of 4.82 µM. No difference in viability was detected between HLFs cultured for 24 h 




Fig. 3.  C9-BA-DANA inhibits sialidase activity in HLFs. (A) A fixed amount of HLF protein 
(1.00 mg) or a fixed number of HLFs (106 cells/reaction) were assayed for sialidase activity for 
4-MU-NANA in the presence of increasing concentrations of C9-BA-DANA. Vertical bars 
represent mean (±SE) sialidase activity expressed as arbitrary fluorescence units/mg protein (left 
Y-axis) or arbitrary fluorescence units/106 cells (right Y-axis) (n = 2). *, decreased sialidase 
activity in the presence versus absence of C9-BA-DANA at P < 0.05. (B) HLFs were cultured 
for 24 h in the presence of 100 µM of C9-BA-DANA or medium alone after which MTT was 
added for an additional 4 h. After DMSO solubilization, the A490 was measured. Vertical bars 
represent mean (±SE) A490 (n = 3). Each result is representative of three independent 
experiments. 
 
Differential expression of NEU1 and PPCA in HAECs, HPMECs and HLFs 
We found that resting baseline total sialidase activities for the 4-MU-NANA substrate, expressed 
as mean ± SE arbitrary fluorescence units/mg cellular protein, were 7866 ± 206 in A549 cells 
(Figure (Figure1A),1A), 12,345 ± 51.9 in HPMECs (Figure (Figure2A)2A) and 2384 ± 9.95 in 
HLFs (Figure (Figure3A).3A). Also resting baseline total sialidase activities, expressed as 
mean ± SE arbitrary fluorescence units/106 cells, were 5000 ± 128 in A549 cells (Figure 
(Figure1A),1A), 8705 ± 36.6 in HPMECs (Figure (Figure2A)2A) and 2386 ± 9.97 in HLFs 
(Figure (Figure3A).3A). The IC50 values for the NEU1 inhibitor, C9-BA-DANA, for sialidase 
activity in each of these same three cell types were 3.74, 13.0 and 4.82 µM, respectively (Figures 
(Figures1A,1A, A,2A,2A, A,3A).3A). The IC50 values for C9-BA-DANA in HPMECs (13.0 
µM) were greater than its IC50 value in A549 cells (3.74 µM) or HLFs (4.82 µM), whereas its 
IC50 values in A549 cells and HLFs were not significantly different. We asked whether 
differential NEU1 and/or protective protein/cathepsin A (PPCA) expression might explain these 
differences in total sialidase activity and IC50 values for C9-BA-DANA between these cell types. 
First, a real-time RT-PCR approach was adopted to detect mRNA for NEU1 and PPCA in A549 
cells, small airway epithelial cells (SAECs), HPMECs and HLFs (Figure (Figure4A).4A). Each 
NEU1 or PPCA mRNA level was normalized to the 18 S rRNA level for the same sample. These 
data indicate that at the mRNA level NEU1 expression was highest in HLFs, followed by 
HPMECs, with the lowest in the two airway epithelia. PPCA mRNA expression was highest in 
HPMECs, followed by HLFs and A549 cells, and lowest in SAECs. To establish relative NEU1 
and PPCA protein expression in these cells, quantitative immunoblotting (Figure (Figure4B)4B) 
was applied where the NEU1 or PPCA signal was normalized to both β-tubulin expression 
(Figure (Figure4C)4C) and cell number (Figure (Figure4D).4D). When normalized to β-tubulin 
or cell number, relative NEU1 protein expression in the four cell types was 
HPMECs > SAECs > HLFs and A549 cells. When normalized to β-tubulin or cell number, 
relative PPCA protein expression in the four cell types was A549 cells > SAECs and 
HLFs > HMPECs. Finally, total sialidase activity normalized to mg protein (Figure 
(Figure4E)4E) or cell number (Figure (Figure4F)4F) was highest in HPMECs, followed by 




Fig. 4.  Differential expression of NEU1 and PPCA in HAECs, HPMECs and HLFs. (A) 
Quantitative RT-PCR analysis of NEU1 and PPCA mRNA levels in A549 cells, SAECs, 
HPMECs and HLFs. Vertical bars represent mean NEU1 or PPCA mRNA levels normalized to 
18 S rRNA mRNA levels. (B) Equivalent numbers of A549 cells (lanes 1, 5), SAECs (lanes 2, 
6), HPMECs (lanes 3, 7) and HLFs (lanes 4, 8) were lysed and equivalent volumes were 
processed for NEU1 (lanes 1–4) and PPCA (lanes 5–8) immunoblotting. To control for protein 
loading and transfer, blots were stripped and reprobed for β-tubulin. IB, immunoblot; IB*, 
immunoblot after stripping. Molecular weight in kDa is indicated on left (lanes 1–4) and right 
(lanes 5–8). (C, D) Densitometric analyses of the blots in (B). Vertical bars represent mean 
(±SE) NEU1 or PPCA signal normalized to β-tubulin signal in the same lane in the same stripped 
and reprobed blot (C) or cell number (D) (n = 2/5). (E, F) A fixed amount of cellular protein 
(A549 cells, 0.63 mg; SAECs, 0.78 mg; HPMECs, 0.71 mg; HLFs, 1.00 mg) (E) or a fixed 
number of A549 cells, SAECs, HPMECs or HLFs (106 cells/reaction) (F) were assayed for 
sialidase activity for 4-MU-NANA. Vertical bars represent mean (±SE) sialidase activity 
corrected for activity in the absence of cells and expressed as arbitrary fluorescence units/mg 
protein (E) or arbitrary fluorescence units/106 cells (F). In (E, F), the n for each experimental 
group is indicated beneath each vertical bar. (G, H) Correlation of sialidase activity for 4-MU-
NANA in A549 cells (1), SAECs (2), HPMECs (3) and HLFs (4) versus (G) NEU1 protein 
levels or (H) PPCA protein levels normalized to β-tubulin or cell number. Each result is 
representative of three independent experiments. 
 
 
The relative sialidase activity for the 4-MU-NANA substrate directly correlated with NEU1 
protein expression levels normalized to β-tubulin (Figure (Figure4G).4G). Although the line of 
correlation between sialidase activities to NEU1 expression normalized to cell number was 
superimposable on that calculated for NEU1 expression normalized to β-tubulin, this correlation 
did not achieve statistical significance (Figure (Figure4G).4G). In contrast to NEU1 levels 
normalized to β-tubulin, relative sialidase activity did not increase with increasing relative PPCA 
protein levels normalized to either β-tubulin or cell number (Figure (Figure4H).4H). To clarify 
this issue, low NEU1-expressing, high PPCA-expressing A549 cells and high NEU1-expressing, 
low PPCA-expressing HPMECs were infected with increasing multiplicities of infection (MOIs) 
of Ad-NEU1 or Ad encoding for PPCA (Ad-PPCA), and the cells processed for NEU1 (Figure 
(Figure5A,E)5A,E) or PPCA (Figure (Figure5C,G)5C,G) immunoblotting and sialidase activity 
for the 4-MU-NANA substrate (Figure (Figure5B,D,F,H).5B,D,F,H). Infection of A549 cells and 
HPMECs with increasing MOIs of Ad-NEU1 or Ad-PPCA dose-dependently increased NEU1 
and PPCA protein expression, respectively (Figure (Figure5A,C,E,G).5A,C,E,G). Ectopic 
overexpression of either NEU1 or PPCA in A549 cells increased sialidase activity by up to 1.7-
fold and >2.6-fold, respectively (Figure (Figure5B,D).5B,D). However, in high NEU1-
expressing, low PPCA-expressing HPMECs, overexpression of NEU1 was not associated with 
increased sialidase activity (Figure (Figure5F),5F), whereas PPCA overexpression was (Figure 
(Figure5H).5H). It is likely that NEU1 overexpression in HPMECs fails to increase sialidase 
activity due to their low expression of PPCA, an established NEU1 chaperone that is required for 
its catalytic activity. To establish the ability of C9-BA-DANA to inhibit sialidase activity 
resulting from ectopic expression of either NEU1 or PPCA in A549 cells and HPMECs, these 
same cells were infected with Ad-NEU1 or Ad-PPCA (MOI = 300), cultured for 48 h and 
assayed for sialidase activity in the presence or absence of C9-BA-DANA (Figure (Figure5I).5I). 
In NEU1-overexpressing A549 cells, C9-BA-DANA decreased sialidase activity by 88.8%, and 
in PPCA-overexpressing A549 cells by 68.6%. In HPMECs, the inhibitor decreased sialidase 
activity in PPCA-overexpressing cells by 64.1%. These combined data indicate that in either 
A549 cells or HPMECs with enhanced sialidase activity provoked by either NEU1 or PPCA 




Fig. 5.  Increased sialidase activity in NEU1- or PPCA-overexpressing A549 cells and HPMECs 
is inhibited by C9-BA-DANA. A549 cells (A–D) and HPMECs (E–H) were infected with 
increasing MOIs of Ad-NEU1 (A, B, E, F) or Ad-PPCA (C, D, G, H). (A, C, E, G) After 48 h, 
the cells were lysed and equal protein aliquots of lysates processed for NEU1 (A, E) or PPCA 
(C, G) immunoblotting. To control for protein loading and transfer, the blots were stripped and 
reprobed for β-tubulin. IB, immunoblot; IB*, immunoblot after stripping. Molecular weight in 
kDa is indicated on left. (B, D, F, H) Sialidase activity for the 4-MU-NANA substrate was 
assayed in A549 cells (B, D) and HPMECs (F, H) infected with increasing MOIs of either Ad-
NEU1 (B, F) or Ad-PPCA (D, H). Vertical bars represent mean (±SE) sialidase activity 
normalized to mg of cellular protein. *, increased sialidase activity in cells infected with Ad-
NEU1 or Ad-PPCA versus uninfected cells at P < 0.05. (I) A549 cells and HPMECs infected 
with Ad-NEU1 or Ad-PPCA (MOI = 300) were cultured for 48 h and assayed for sialidase 
activity for the 4-MU-NANA substrate in the presence of 134 μM of C9-BA-DANA or medium 
alone. Vertical bars represent mean (±SE) sialidase activity corrected for activity in the absence 
of cells and normalized to mg of cellular protein. *, increased sialidase activity in Ad-NEU1-
infected or Ad-PPCA-infected cells versus uninfected cells at P < 0.05. **, decreased sialidase 
activity in C9-BA-DANA-treated cells versus untreated cells at P < 0.05. The n for each 
experimental group is indicated in each panel. Each result is representative of three independent 
experiments. 
 
C9-BA-DANA displays less inhibitory activity for neuraminidases expressed by 
Arthrobacter ureafaciens, Clostridium perfringens and Vibrio cholerae 
We reported that C9-BA-DANA selectively inhibited human NEU1 (IC50 = 10 µM) relative to 
human NEU2, -3 and -4 (IC50 > 1000 µM) (Magesh et al. 2008). Among the four known human 
NEUs, NEU1 shares the least homology with the other three (Monti et al. 2002, 2010; Miyagi 
and Yamaguchi 2012). In fact, NEU1 might be more closely related to some prokaryotic 
neuraminidases than the other human NEUs (Kiyohara et al. 2011). Furthermore, numerous 
microbes that express their own neuraminidases are known to colonize, or in some instances, 
infect humans (Kim et al. 2011; Lewis and Lewis 2012). To establish whether C9-BA-DANA 
might inhibit bacterial neuraminidases, we established the IC50 for C9-BA-DANA for each of 
three bacterial neuraminidases selected for their phylogenetic relatedness to human NEU1 
(Kiyohara et al. 2011) (Figure (Figure6).6). We found the IC50 for C9-BA-DANA to be 890 µM 
for Arthrobacter ureafaciens neuraminidase (Figure (Figure6A),6A), and >1000 µM for both 
Clostridium perfringens neuraminidase NanI (Figure (Figure6B)6B) and Vibrio cholerae 
neuraminidase (Figure (Figure6C).6C). These combined data indicate that C9-BA-DANA is 
selective for human NEU1 not only relative to the other human NEUs (Magesh et al. 2008), but 




Fig. 6.  C9-BA-DANA exerts far less inhibitory activity for prokaryotic neuraminidases. Fixed 
concentrations of the neuraminidases expressed by (A) A. ureafaciens (7.5 ng/mL), (B) C. 
perfringens (NanI) (40 ng/mL) and (C) V. cholerae (625 ng/mL) were each assayed for sialidase 
activity for 4-MU-NANA in the presence of increasing concentrations of C9-BA-DANA. The 
concentration chosen for each bacterial neuraminidase generated catalytic activity for the 4-MU-
NANA substrate comparable to that seen with the simultaneous positive control using A549 cells 
at 106 cells/reaction. Each symbol represents mean (±SE) neuraminidase activity corrected for 
activity in the absence of bacterial neuramindase and expressed as arbitrary fluorescence 
units/mg protein (n = 2/3). The broken line in each panel represents the linear trendline with the 
corresponding equation and correlation coefficient (R2) value determined using Microsoft Excel. 
Insert in (B) represents the silver-stained gel of resolved C. perfringens neuraminidase 
preparation. Molecular weight in kDa indicated on left. Arrow on right indicates NanI band of 
interest. Each result is representative of two or three independent experiments. 
 
Predicted steric hindrances to C9-BA-DANA in bacterial neuraminidases 
To better understand why C9-BA-DANA is selective for NEU1, not only among the human 
sialidases (Magesh et al. 2008), but also relative to the bacterial neuraminidases studied here, we 
compared the X-ray crystal structures of C. perfringens NanI (Protein Database ID 2VK6) and 
the V. cholerae neuraminidase (Protein Database ID 1W0O) to models of the neuraminidase of 
A. ureafaciens and NEU1 bound with C9-BA-DANA, for which no high-resolution structures are 
available. Importantly, DANA, upon which C9-BA-DANA is based, is able to bind and inhibit 
all of the neuraminidases/sialidases used in this study (Meindi and Tuppy 1969; Burmeister et al. 
1993). After superimposition of the X-ray crystal structures and models, we examined the results 
for any causes of gross steric or electrostatic incompatibility between C9-BA-DANA and the 
bacterial neuraminidases. We found that universally, the polypeptide loop between the seventh 
and eighth strands of the β-propeller fold (the β7–β8 loop) is substantially longer in the bacterial 
neuraminidases compared with the β7–β8 loop of human NEU1 (Figure (Figure7A–C).7A–C). 
Modeling studies predict that the longer β7–β8 loops of the bacterial neuraminidases may 
interfere with C9-BA-DANA accessibility to their catalytic domains. These steric clashes 
between amino acid side-chains extending from these loops and the n-butyl group linked to the 
C9 position of the inhibitor are absent in the NEU1-C9-BA-DANA model. Furthermore, amino 
acid sequence alignments between human NEU1 and human NEU2, -3 and -4 indicate that like 
the bacterial neuraminidases the β7–β8 loops in NEU2, -3 and -4 are longer than the β7–β8 loop 
in NEU1 (Figure (Figure7D)7D) (Magesh et al. 2006). The presence of an extended β7–β8 loop 
in NEU2, -3 and -4 might explain their relative resistance to inhibition by C9-BA-DANA, while 
absence of the n-butyl group in DANA might account for its ability to inhibit all four human 
sialidases. However, the ability of DANA molecules with phenyl-containing substituents at C9 to 
inhibit NEU2 and NEU3 argues that accommodation of larger substituents at C9 is possible for 
sialidases with longer β7–β8 loops under some circumstances, suggesting that favorable 
interactions with phenyl rings may drive loop remodeling (Magesh et al. 2008; Zhang et al. 
2013). Similarly, a DANA-derivative with a large polar C9-substituent was found to be a highly 
potent inhibitor of NEU4, suggesting that electrostatic interactions with a methanol moiety at the 
tip of a triazol ring were similarly stabilizing (Albohy et al. 2013). The ability of NEU1 to 
accommodate a variety of hydrophobic moieties at C9, unlike NEU2, -3 and -4 (and the bacterial 
neuraminidases studied here) may indicate that these substituents prevent the β7–β8 loops of 
NEU2, -3 and -4 from adopting their native structures without stabilizing any alternative 
conformations. As previously reported (Magesh et al. 2008), other potential sites in NEU2, -3 
and -4 for steric hindrance with C9-BA-DANA were identified, including a shared Tyr residue 




Fig. 7.  Predicted steric hindrance to C9-BA-DANA binding to bacterial neuraminidases. 
Structural superimposition of the C9-BA-DANA–NEU1 complex (gray) with (A) A. ureafaciens 
neuraminidase (orange), (B) C. perfringens NanI (blue) and (C) V. cholerae neuraminidase 
(green). Only the β7–β8 loops of the bacterial neuraminidases are depicted. V. cholerae 
(National Center for Biotechnology Information, Protein Database ID #1W0O) and C. 
perfringens (National Center for Biotechnology Information, Protein Database ID #2VK6) 
neuraminidase structures are X-ray crystal structures. A. ureafaciens neuraminidase and NEU1 
structures are based on homology modeling with the NEU2 X-ray crystal structure. (D) Amino 
acid sequence alignments of the β7–β8 loop from human NEU1, -2, -3 and -4 and the three 
bacterial neuraminidases are shown. This figure is available in black and white in print and in 
color at Glycobiology online. 
 
C9-BA-DANA inhibits flagellin-induced increases in mouse lung sialidase 
activity in vivo 
In wild type mice, the highest levels of sialidase activity were detected in kidney tissue, and 
when compared with the kidney tissues of NEU1-null mice, sialidase activity could be almost 
exclusively ascribed to NEU1 (de Geest et al. 2002). First, to test whether C9-BA-DANA could 
inhibit NEU1 catalytic activity in vivo, total sialidase activities for the 4-MU-NANA substrate in 
kidney tissues obtained from mice preadministered with the inhibitor or PBS vehicle alone were 
assayed (Figure (Figure8A).8A). Prior administration of C9-BA-DANA inhibited renal sialidase 
activity by 90.6% compared with the PBS controls. Preadministration of the broad spectrum 





Fig. 8.  C9-BA-DANA prevents flagellin-induced increases in mouse lung sialidase activities in 
vivo. (A) Mice were injected intraperitoneally with 15 μg/kg of C9-BA-DANA (n = 3) or DANA 
(n = 3), or PBS vehicle alone (n = 3). After 24 h, mice were euthanized and kidneys were 
harvested, weighed and homogenized. Kidney homogenates were processed for assays for total 
protein levels and total sialidase activity for the 4-MU-NANA substrate. Vertical bars represent 
mean (±SE) total kidney sialidase activity in arbitrary fluorescence units/mg protein. *, 
decreased sialidase activity in kidneys of C9-BA-DANA- or DANA-treated versus  PBS-infused 
mice at P < 0.05. (B) Mice were injected intraperitoneally with 15 μg/kg of C9-BA-DANA 
(n = 13) or DANA (n = 14) or PBS vehicle alone (n = 29). After 24 h, mice pretreated 
intraperitoneally with C9-BA-DANA were challenged intranasally with 100 ng/mouse of Pa-
derived flagellin (n = 10) or PBS (n = 3), mice pretreated with DANA were challenged with 
flagellin (n = 7) or PBS (n = 7), and mice pretreated with PBS were challenged with flagellin 
(n = 13) or PBS (n = 16). After 4 h, mice were euthanized and lungs were harvested, weighed 
and homogenized. Lung homogenates were processed for assays for total protein levels and total 
sialidase activity for the 4-MU-NANA substrate. Vertical bars represent mean (±SE) lung 
sialidase activity corrected for activity in the absence of a tissue sample and expressed as 
arbitrary fluorescence units/mg protein. *, decreased sialidase activity in C9-BA-DANA- or 
DANA-treated lung tissue versus PBS controls at P < 0.05. **, increased sialidase activity in 
flagellin-stimulated lung tissue versus PBS control at P < 0.05. Each result is representative of 
three independent experiments. 
 
 
C9-BA-DANA dose-dependently inhibited sialidase activity in in vitro cultures of HAECs 
(Figure (Figure1A),1A), HPMECs (Figure (Figure2A)2A) and HLFs (Figure (Figure3A).3A). 
Furthermore, stimulation of HAECs with Pa flagellin increased NEU1-mediated MUC1-ED 
desialylation, adhesiveness for Pa and shedding, all of which were inhibited by C9-BA-DANA 
(Figure (Figure1C–F).1C–F). We asked whether C9-BA-DANA might inhibit total lung sialidase 
activity in an in vivo setting. In the lungs of PBS-administered control mice, basal levels of total 
sialidase activity for the 4-MU-NANA substrate were detected (Figure (Figure8B).8B). 
Administration of C9-BA-DANA 24 h prior to harvesting lungs reduced baseline sialidase 
activity by 59.7%. In flagellin-challenged mice, total lung sialidase activity increased by 46.7% 
compared to the PBS-administered controls in the absence of C9-BA-DANA. Preadministration 
of C9-BA-DANA completely prevented the flagellin-induced increase in lung sialidase activity. 
Finally, preadministration of DANA also inhibited lung sialidase activity in the absence or 
presence of the flagellin stimulus, both of which were equivalent to the inhibition seen by C9-
BA-DANA. These findings indicate that the ability of C9-BA-DANA to inhibit sialidase activity 
in HAECs (Figure (Figure1A),1A), HPMECs (Figure (Figure2A)2A) and HLFs (Figure 
(Figure3A)3A) can be extended to an intact in vivo model. Sialidases other than NEU1 are 
known to be expressed in lung tissue (Bonten et al. 1996; Igdoura et al. 1998; Cross et al. 2012; 
Lillehoj et al. 2012, 2015). However, the decreases in flagellin-provoked lung sialidase activities 
in response to C9-BA-DANA and the more broad spectrum DANA were comparable (Figure 
(Figure8B),8B), not supporting the involvement of sialidases other than NEU1. It is still 
conceivable, however, that one or more of these other sialidases might explain the C9-BA-
DANA-unresponsive lung sialidase activity. 
 
Discussion 
In the current studies, C9-BA-DANA reduced total sialidase activity in lung epithelia (Figure 
(Figure1A),1A), endothelia (Figure (Figure2A)2A) and fibroblasts (Figure (Figure3A).3A). In 
HAECs, at the mRNA level, NEU1 is expressed at levels >7500-fold greater than NEU2, >500-
fold greater than NEU3 and >4000-fold greater than NEU4 (Lillehoj et al. 2012). In HPMECs, 
NEU1 is expressed at levels >8700-fold greater than NEU2, >500-fold greater than NEU3 and 
>5000-fold greater than NEU4 (Cross et al. 2012). Prior siRNA-induced silencing of NEU1 in 
both lung epithelia and endothelia reduced total sialidase activity for the 4-MU-NANA substrate 
by >70% (Cross et al. 2012; Lillehoj et al. 2012). The second most abundant sialidase in these 
cells, NEU3, may be less active for the 4-MU-NANA substrate (Wada et al. 1999). However, a 
more recent report indicates otherwise (Smutova et al. 2014). These combined data indicate that 
C9-BA-DANA can inhibit total sialidase activity in HAECs, HPMECs and HLFs, and that 
almost all of this sialidase activity can be ascribed to NEU1. 
Of the four known mammalian sialidases, NEU1 is the most abundant and widely distributed 
(Monti et al. 2002, 2010; Miyagi and Yamaguchi 2012). NEU1, like many other gene products, 
is differentially expressed in various organs and tissues (Bonten et al. 1996; Igdoura et al. 1998). 
The human NEU1 transcript appears to be most abundant in pancreas, followed in decreasing 
order by skeletal muscle, kidney, heart, placenta, liver, lung and at very low levels, brain (Bonten 
et al. 1996). In the mouse, the highest levels of NEU1 mRNA expression were found in kidney 
and epididymis, with moderate levels in the brain and spinal cord, and lower levels in adrenal, 
liver, lung, spleen and heart (Igdoura et al. 1998). Although NEU1 gene expression in the lung is 
relatively modest, it is absolutely essential to normal lung development (Starcher et al. 2008). 
NEU1-null mice exhibit impaired septation and alveolarization resulting in enlarged air spaces. 
Just as NEU1 is differentially expressed throughout human tissues (Bonten et al. 1996), we now 
have demonstrated that its expression within the lung itself is heterogeneous for distinct cell 
types. 
The IC50 in HPMECs (13.0 µM) was 3.5-fold higher than that established for A549 cells (3.74 
µM) and 2.7-fold higher than that found for HLFs (4.82 µM). Several properties might explain 
the requirement for higher concentrations of C9-BA-DANA in HPMECs to provide equivalent 
inhibition to that seen in the other two cell types. Total baseline sialidase activity in resting, 
unstimulated HMPECs (Figure (Figure2A)2A) was >1.7-fold higher than that detected in an 
equivalent number of resting, unstimulated A549 cells (Figure (Figure1A)1A) and >3.6-fold 
higher than that found in HLFs (Figure (Figure3A).3A). We asked whether differential 
expression of NEU1 and/or its transport/chaperone protein, PPCA, might explain the higher 
sialidase activity in HPMECs. We found that NEU1 protein expression normalized to β-tubulin 
or cell number was >1.9-fold higher in HPMECs compared to its expression in A549 cells, >1.2-
fold higher compared to its expression in SAECs and >1.7-fold higher compared to its 
expression in HLFs (Figure (Figure4C,D).4C,D). In contrast, normalized PPCA protein 
expression was lowest in HPMECs and highest in A549 cells (Figure (Figure4C,D).4C,D). 
Among the four cell types analyzed, increasing NEU1 protein levels significantly correlated with 
increasing sialidase activity for the 4-MU-NANA substrate (Figure (Figure4G).4G). 
Unexpectedly, increasing PPCA protein levels did not correlate with sialidase activity (Figure 
(Figure4H).4H). To further clarify the contributions of NEU1 and PPCA to cellular sialidase 
activity, NEU1 and PPCA each were dose-dependently overexpressed in low NEU1-expressing, 
high PPCA-expressing A549 cells and high NEU1-expressing, low PPCA-expressing HPMECs 
(Figure (Figure5).5). In A549 cells, overexpression of either NEU1 or PPCA increased sialidase 
activity (Figure (Figure5B,D),5B,D), whereas in HPMECs, PPCA overexpression increased 
sialidase activity (Figure (Figure5H)5H) while NEU1 overexpression did not (Figure 
(Figure5F).5F). These combined data indicate that (1) NEU1 and PPCA protein expression and 
sialidase activity differ in distinct cell types and tissues, (2) NEU1 protein expression correlates 
with sialidase activity, (3) endogenous PPCA expression can be a limiting factor for NEU1-
mediated sialidase activity and (4) differential NEU1 and/or PPCA expression may dictate 
cellular responsiveness to C9-BA-DANA. 
The experimental conditions required for each of the essays described in this study might 
contribute to the inconsistent effects of C9-BA-DANA. First, the 4-MU-NANA assay for 
sialidase catalytic activity (Figures (Figures1A,1A, A,2A,2A, A,3A,3A, A,4E,F,4E,F, 
E,F,5B,D,F,H,I)5B,D,F,H,I) involves treatment of cells with the detergent, Triton X-100, which 
permeabilizes the plasma membrane likely permitting increased entry into and/or exit from cells. 
The PNA lectin blotting (Figure (Figure1C,D)1C,D) and adhesion assays (Figure (Figure1E)1E) 
are performed within 30 min of the flagellin stimulus, whereas the MUC1-ED shedding 
experiments (Figure (Figure1F)1F) are carried out after 24 h. The stability of C9-BA-DANA in 
aqueous culture medium at 37°C over time has not been defined. MUC1-ED exhibits a β-turn 
helix resulting from its high proline content (Fontenot et al. 1995). This extended rod-like 
conformation allows MUC1 to protrude higher above the airway epithelial surface than most 
membrane-associated proteins. MUC1-ED desialylation and altered bacterial adhesion likely 
occur at the outermost position of glycan chains where the terminal sialic acid residues are 
located (Lillehoj et al. 2013). In the PNA lectin blotting studies which assayed MUC1-ED 
desialylation, C9-BA-DANA at 10 µM inhibited desialylation by 42.0%, and at 100 µM, by 
78.7% (Figure (Figure1C,D).1C,D). In the Pa adhesion assays, C9-BA-DANA at 10 µM 
inhibited adhesion by 43.1%, and at 100 µM, by 67.5% (Figure (Figure1E).1E). In contrast, the 
protease recognition site where proteolytic cleavage and shedding of the MUC1-ED occur is 
located at a Gly-Ser peptide bond located 58 amino acids upstream of the transmembrane domain 
within the extracellular, juxtamembranous region (Parry et al. 2001). In the MUC1-ED shedding 
assays, C9-BA-DANA at 10 µM inhibited shedding only by 23.8%, and at 100 µM, only by 
46.7% (Figure (Figure1F).1F). Whether such differences in the site of NEU1 activity and sialic 
acid removal influences, the ability of C9-BA-DANA to interact with NEU1 to inhibit its 
catalytic activity is unclear. Other possible explanations might include differences in intracellular 
and/or cell surface pH, and/or distinct cellular volumes and/or plasma membrane/glycocalyx 
properties that dictate C9-BA-DANA entry into the intracellular compartment and accessibility 
to the NEU1 sialidase. Unlike the experiments performed with HAECs (Figure (Figure1C–
F),1C–F), the sialidase activity in HPMECs was comprised of both endogeneous NEU1 and 
ectopically expressed NEU1 through Ad-NEU1 infection (Figure (Figure2B–E).2B–E). C9-BA-
DANA dramatically reduced sialidase activity in NEU1-overexpressing cells (Figure 
(Figure5I).5I). Whether endogenous and ectopically expressed NEU1 are equally catalytically 
active on a molar basis and/or equally susceptible to the inhibitory activity of C9-BA-DANA 
have not been tested. 
The selectivity of C9-BA-DANA for human NEU1, relative to bacterial neuraminidases, may 
have implications for its potential therapeutic application. A number of commensal bacteria 
express neuraminidases that can facilitate their acquisition of carbohydrate nutrients and regulate 
their physical presentation to host tissues and recognition by the immune system (Kim et al. 
2011; Lewis and Lewis 2012). Since any intervention that disrupts bacterial neuraminidases 
might exert an unpredictable impact on host–microbe and microbe–microbe interactions, a more 
selective approach is theoretically preferable. 
NEU1 reportedly influences multiple biological processes. Evidence exists to support a role for 
NEU1 in aspects of microbial pathogenesis, innate immunity and the sepsis syndrome (Cross et 
al. 2003; Grewal et al. 2008; Amith et al. 2009, 2010; Seyrantepe et al. 2010; Abdulkhalek et al. 
2011, 2012; Feng et al. 2012, 2013; Lillehoj et al. 2012, 2015; Abdulkhalek and Szewczuk 
2013). NEU1 participates in TLR activation (Amith et al. 2009, 2010; Abdulkhalek et al. 
2011, 2012; Feng et al. 2012; Abdulkhalek and Szewczuk 2013), including TLR4 responsiveness 
to its ligand, bacterial lipopolysaccharide (LPS) or endotoxin (Amith et al. 2010; Abdulkhalek et 
al. 2011; Feng et al. 2012), and influences macrophage phagocytosis (Seyrantepe et al. 2010). Pa 
hijacks human NEU1 to desialylate its receptor, the MUC1-ED, which in turn, increases bacterial 
adhesion to and invasion of the airway epithelium (Lillehoj et al. 2012, 2015). Sialidase activity 
regulates complement-mediated pulmonary leukostasis and transendothelial recruitment of 
granulocytes into the bronchoalveolar compartment (Cross et al. 2003), and finally, the 
development of endotoxin-induced acute lung injury (Feng et al. 2013). In one study, the 
coagulopathy associated with Streptococcus pneumoniae sepsis was ascribed to bacterial 
neuraminidase (Grewal et al. 2008). The role(s) of one or more human sialidase(s) was not 
considered. Sialic acid and its metabolism also reportedly contribute to the atherogenic process 
(Tertov et al. 1998; Golovanova et al. 2002; Mochizuki et al. 2002; Cuniberti et al. 2005; Gopaul 
and Crook 2006; Gayral et al. 2014). Serum sialic acid is a predictive biomarker for coronary 
artery disease (Gopaul and Crook 2006) and desialylation of low-density lipoproteins (Tertov et 
al. 1998) and the arterial surface (Cuniberti et al. 2005) facilitates neointimal development and 
atherogenesis. Sialidase activity is elevated in the atherosclerotic aortic intima (Golovanova et al. 
2002) and NEU1 is essential to elastin receptor signaling (Hinek et al. 2006, 2008; Duca et al. 
2007; Starcher et al. 2008), which in turn, increases arterial smooth muscle proliferation and 
enhances atheroma plaque size progression (Mochizuki et al. 2002; Gayral et al. 2014). Finally, 
NEU1 overexpression impairs the endothelial migratory response to injury (Figure 
(Figure2C,D)2C,D) (Cross et al. 2012; Lee et al. 2014). More recently, we reported that NEU1 
expression is upregulated in the lungs of IPF patients (Luzina et al. 2016). It is conceivable that a 
NEU1-selective sialidase inhibitor such as C9-BA-DANA might offer a novel therapeutic 
intervention for sepsis, atherosclerotic arterial disease, IPF and/or other human disease states. 
 
Materials and methods 
Reagents 
Precast SDS-polyacrylamide gels were from Novex (San Diego, CA). Polyvinylidene fluoride 
(PVDF) membrane was from Millipore (Bedford, MA). Enhanced chemiluminescence reagents 
and prestained protein molecular weight markers were from BioRad (Hercules, CA). Mouse 
antihuman NEU1 monoclonal antibody was from Origene (Rockville, MD). Rabbit anti-PPCA 
antibody was from Abcam (Cambridge, MA). Mouse anti-Physarum β-tubulin antibody was 
from Boehringer-Mannheim (Indianapolis, IN). Horseradish peroxidase-conjugated goat 
antirabbit and goat-antimouse secondary antibodies were from Cell Signaling Technology 
(Danvers, MA). PNA and PNA-agarose were from Vector Laboratories (Burlingame, CA). 
DANA was from Calbiochem (San Diego, CA). C9-BA-DANA was prepared as previously 
described (Magesh et al. 2008). 
Human lung cell cultures 
A549 cells are an alveolar type II cell line derived from a lung adenocarcinoma (American Type 
Culture Collection, Manassas, VA). A549 cells were cultured in Dulbecco's modified Eagle's 
medium (DMEM) containing 10% fetal bovine serum (Hyclone Laboratories, Logan, UT), 50 
units/mL penicillin and 50 µg/mL streptomycin, as described (Lillehoj et al. 2012). Human 
primary SAECs isolated from the distal portion of the bronchioles (PromoCell, Heidelberg, 
Germany) were cultured as described (Lillehoj et al. 2012, 2015). SAECs were studied in 
passages 2–4. HPMECs (PromoCell) were cultured in endothelial cell growth medium (MV-2, 
PromoCell) containing growth medium supplement mix (PromoCell) as described (Cross et al. 
2012; Lee et al. 2014). HPMECs were studied in passages 4–7. Primary normal adult HLFs 
(Lonza, Rockland, ME) were cultured in DMEM supplemented with 2.0 mM glutamine, 2.0 mM 
sodium pyruvate, 50 mg/L gentamicin and 10% fetal bovine serum, as described (Nacu et al. 
2008). All HLF cultures were passaged by trypsinization and used for experiments in passages 
3−7. 
Fluorometric assay for sialidase activity 
A549 cells, HPMECs and HLFs (106 cells/reaction) were suspended in 200 µL of 500 mM 
sodium acetate, pH 4.4 containing 0.1% Triton X-100 and protease inhibitor mixture (Roche 
Applied Science, Branford, CT) in the presence of increasing concentrations of C9-BA-DANA. 
The cell-containing mixtures were then incubated for 1 h at 37°C with 25 µL of 2.0 mM 4-MU-
NANA, mixing the tubes every 15 min. The sialidase reaction was terminated by addition of 1.0 
mL of 133 mM glycine, pH 10.3, 60 mM NaCl and 0.083 M Na2CO3, after which fluorescence 
intensity was measured with a fluorometer (excitation at 355 nm; emission at 460 nm), as 
described (Cross et al. 2012; Lillehoj et al. 2012). Half maximal inhibitory concentration (IC50) 
values of C9-BA-DANA were calculated using the ED50V10 Microsoft Excel add-in 
(http://www.sciencegateway.org/protocols/cellbio/drug/hcic50.htm) with background corrected 
fluorescence values and log10-transformed C9-BA-DANA concentrations. The same 4-MU-
NANA fluorogenic substrate was used to establish the IC50 values of C9-BA-DANA for 
neuraminidases expressed by A. ureafaciens (Roche), C. perfringens (Sigma, St. Louis, MO) and 
V. cholerae (Roche, Indianapolis, IN). C. perfringens is known to express three distinct 
neuraminidases, NanH (42.8 kDa), NanI (77.4 kDa), and NanJ (~140 kDa) (Newstead et al. 
2008). Since the commercial source for the clostridial neuraminidase could not specify, which 
neuraminidase(s) was contained in their product, the preparation was resolved by SDS-PAGE 
and the gel processed for silver staining according to the manufacturer's protocol (Life 
Technologies, Carlsbad, CA). The resolved preparation contained a single protein band with a 
molecular weight of ~77.0 kDa, compatible with NanI. To control for interassay variability, a 
simultaneous positive control using A549 cells at 106 cells/reaction was included with each 
assay. To address the dissimilar purities and specific activities for the bacterial neuraminidases, a 
concentration range for each enzyme was tested for catalytic activity for the 4-MU-NANA 
substrate, and a concentration that generated catalytic activity comparable to that seen with the 
A549 cell control was chosen for IC50 studies for the C9-BA-DANA inhibitor. The concentration 
chosen was 7.5 ng/mL for A. ureafaciens neuraminidase, 40 ng/mL for C. perfringens NanI and 
625 ng/mL for V. cholerae neuraminidase. 
Pa culture and flagellin purification 
Pa strain PAO1 was cultured overnight in Luria-Bertani broth, washed twice with PBS, 
resuspended in PBS containing 2.0 mg/mL glucose and quantified spectrophotometrically at 
A600, as described (Lillehoj et al. 2012, 2015). An overnight culture of Pa was centrifuged at 
5000 × g for 30 min, resuspended in Krebs-Ringer buffer, and incubated for 1 h at 37°C, as 
described (Lillehoj et al. 2012, 2015). The bacteria were removed by centrifugation, and the 
supernatant was filtered through a 0.22-µm-pore membrane (Millipore) and boiled for 20 min. 
The supernatant was concentrated by ultrafiltration (Millipore; 30-kDa cutoff), adjusted to pH 
6.0, and incubated for 30 min at room temperature with 0.5 mL of Macro-Prep High S support, 
pH 6.0. The matrix was removed by centrifugation, and the flagellin-containing supernatant was 
applied to a 2.0-mL Macro-Prep High Q column. The column was washed with 20 mM Tris-
HCl, pH 8.0 and flagellin was eluted with 100 mL of a linear 0.0–1.0 M NaCl gradient. Fractions 
(1.0 mL) were collected and analyzed for the 50-kDa flagellin protein band by SDS-PAGE. 
Immunoblots were probed with rabbit anti-Pa flagellin antibody (provided by Dr. Dan Wozniak, 
Wake Forest University, Winston-Salem, NC) and with rabbit antipilin antibody (provided by 
Dr. Randy Irvin, University of Alberta, Alberta, Canada) to confirm the absence of pilin 
contamination. Flagellin-containing fractions were preadsorbed with polymyxin B-agarose to 
remove bacterial LPS, after which less than 0.1 LPS units/µg of protein was detected by the 
Limulus amebocyte lysate assay. 
PNA lectin blotting of desialylated MUC1-ED 
A549 cells were incubated for 30 min at 37°C with 10 ng/mL flagellin or medium alone, 
solubilized with lysis buffer as described (Lillehoj et al. 2012, 2015), and 1.0 mg aliquots were 
incubated with PNA immobilized on Sepharose beads (Vector Labs, Burlingame, CA) to 
selectively enrich for PNA-binding proteins. The PNA-bound proteins were resolved by SDS-
PAGE, transferred to PVDF, and the blots incubated with mouse antihuman MUC1-ED antibody 
(clone GP1.4, Biomedia, Foster City, CA), as described (Lillehoj et al. 2012, 2015). Asialofetuin 
(1.0 µg) was used as a positive control for PNA-binding proteins, whereas fetuin (1.0 µg) was 
used as a negative control. 
Pa adhesion to HAECs 
A549 cells were incubated for 30 min at 37°C with 10 ng/mL of Pa-derived flagellin or medium 
alone, after which they were washed twice with PBS, fixed for 10 min with 2.5% glutaraldehyde 
in PBS at room temperature, and washed three times with PBS as described (Lillehoj et al. 2012, 
2015). Fixed cells (2.0 × 105/well) in 24-well plates were incubated with 2.0 × 107 colony-
forming units (CFU)/well of PAO1 in 0.5 mL for 40 min at 37°C and washed three times with 
PBS. Bound bacteria were released with 0.05% trypsin, and bound CFUs quantified as described 
(Lillehoj et al. 2012, 2015). 
ELISA for MUC1-ED 
A549 cell-conditioned culture media were centrifuged at 10,000 × g for 10 min at 4°C, added in 
triplicate to 96-well ELISA plates (MaxiSorb; Nalge Nunc, Rochester, NY) and incubated 
overnight at 4°C. Wells were blocked for 1 h at room temperature with PBS, pH 7.0, containing 
10 mg/mL bovine serum albumin and 50 mg/mL sucrose, and washed with PBS containing 
0.05% Tween-20 (PBS-T). The samples were reacted for 2 h at room temperature with 200 
µg/mL of primary MUC1-ED antibody, washed with PBS-T, reacted for 2 h at room temperature 
with 200 µg/mL of peroxidase-conjugated goat-antimouse IgG secondary antibody (KPL, 
Gaithersburg, MD) and washed with PBS-T. Bound antibodies were detected with 
tetramethylbenzidine substrate (SureBlue, KPL). The substrate reaction was stopped with 1 N 
HCl, and A450 measured using a microplate spectrophotometer (Dexall, Gaithersburg, MD), as 
described (Lillehoj et al. 2015). 
 
HPMEC migration in a wounding assay 
HPMECs were seeded at 2.0 × 105 cells/well in the wells of a 24-well plate (Corning, Corning, 
NY), and after 3 h, infected with recombinant Ad-NEU1 or Ad-GFP (MOI = 100), as described 
(Lee et al. 2014). The HPMECs were cultured for 48 h to confluence. Using a sterile 200 µL 
pipette tip, a single wound was made across the diameter of each monolayer, after which the cell 
debris was removed by washing with HEPES, as described (Cross et al. 2012; Lee et al. 2014). 
The wounded monolayers were then incubated for 24 h in the absence or presence of 134 µM of 
C9-BA-DANA. At 24 h, photomicrographs of each well were taken with a Nikon inverted 
microscope. HPMEC area was calculated using ImageJ software for comparison with that 
observed in the same wounded monolayer at 0 h, as a measure of migration into the wound. 
In vitro HPMEC capillary-like tube formation 
Each well of a 96-well plate was coated with 50 µL of Matrigel (10 mg/mL; BD Biosciences, 
Sparks, MD), as described with modifications (Lee et al. 2014). Briefly, Matrigel was allowed to 
polymerize for 1 h at room temperature in each of the wells, followed by 1 h at 37°C in a 
humidified atmosphere at 5% CO2. HPMECs infected with Ad-GFP or Ad-NEU1 (MOI = 100) 
were seeded at 7.5 × 103 cells/well onto the Matrigel-coated wells, in the presence 134 µM of 
C9-BA-DANA or medium alone. At 6 h, tubular structures were photographed through a Nikon 
inverted microscope, and segments of capillary-like tubes per high power field (HPF) were 
counted. 
Quantitative RT-PCR for human NEU1 and PPCA transcripts 
Total cellular RNA was extracted from A549 cells, SAECs, HPMECs and HLFs, as described 
(Cross et al. 2012; Lillehoj et al. 2012). RNA purity was established with the 260/280 nm 
absorption ratio (>1.90). Total RNA (1.0 µg) was treated with DNase I (Invitrogen, Carlsbad, 
CA) for 15 min and reverse transcribed using avian myelobastosis virus reverse transcriptase and 
poly(T) primer (Promega, Madison, WI). The resulting cDNA was quantified by PCR using 
SYBR Green PCR Master Mix and an ABI Prism 7900HT cycler. Primers for detection of 
human NEU1 and PPCA mRNAs were designed using Primer Express 2.0 (Applied Biosystems, 
Foster City, CA), as described (Cross et al. 2012; Lillehoj et al. 2012). Relative NEU1 and PPCA 
gene expression was calculated using the 2−ΔΔCt method where NEU1 and PPCA transcripts were 
normalized to the levels of 18 S rRNA transcripts as the internal control, as described (Cross et 
al. 2012; Lillehoj et al. 2012). 
Quantitative immunoblotting for human NEU1 and PPCA proteins 
To establish relative NEU1 and PPCA protein expression in various human lung cells, equivalent 
numbers of A549 cells, SAECs, HPMECs and HLFs were lysed and equivalent lysate volumes 
were processed for NEU1 and PPCA immunoblotting, as described (Cross et al. 2012; Lillehoj et 
al. 2012; Lee et al. 2014). To control for protein loading and transfer for the NEU1 and PPCA 
immunoblots, the blots were stripped and reprobed for β-tubulin. NEU1 and PPCA signals were 
normalized to both cell number and β-tubulin signal in the same lane in the same stripped and 
reprobed blot. 
Adenoviral constructs encoding for PPCA 
A plasmid encoding for human PPCA (pSCTop-PPCA) was generously provided by Drs E. 
Bonten and A. d'Azzo (St. Jude Children's Research Hospital, Memphis, TN). A 
recombinant Ad-PPCA was generated using the AdEasy Ad Vector System (Stratagene, La Jolla, 
CA) as described for other gene products (Cross et al. 2012; Lillehoj et al. 2012). Briefly, the 
pSCTop-PPCA was digested with SalI and NotI and subcloned into a shuttle vector (pShuttle 
CMV, Stratagene) using the same restriction enzymes followed by ligation. The shuttle plasmid 
was linearized through PmeI digestion and, with the Ad backbone plasmid (pAdEasy-1, 
Qbiogene, Carlsbad, CA), was used to co-transform electrocompetent Escherichia coli BJ5183 
cells to produce the recombinant plasmid, Ad-PPCA. Recombinants were selected for kanamycin 
resistance and screened for recombination by Pac1 restriction enzyme analysis and agarose gel 
electrophoresis. The correct recombinant plasmids were used to transform DH5α cells, and 
bacterial lysates were passed through Maxiprep columns (Qiagen, Valencia, CA) for purification. 
Ad-PPCA was linearized with PacI digestion and transfected, in the presence of Lipofectamine 
(Invitrogen), into AD-293 cells. After 7–10 d, cells were scraped off flasks with a rubber 
policeman and subjected to three freeze-thaw cycles, and virus was harvested in the supernatants 
for presentation to fresh AD-293 cells and titration in a plaque-forming assay. A549 cells and 
HPMECs were transiently infected with packaged Ad-PPCA at increasing MOIs and after 48 h 
were lysed, and the lysates processed for PPCA immunoblotting and the fluorometric assay for 
sialidase activity. 
Cell viability 
A549 cells, HPMECs and HLFs were seeded into the wells of 48-well plates and cultured to 80% 
confluence. The cells were cultured for 20 h in the presence of 100 µM of C9-BA-DANA or 
medium alone, after which 250 ng/mL of 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium 
bromide (MTT) was added for an additional 4 h incubation. The medium was aspirated and 100 
µL of DMSO added and mixed by pipette. After 10 min, each well was again mixed and A490 
measured. 
Homology modeling of the C9-BA-DANA–NEU1 complex with bacterial 
neruaminidases 
Homology models of human NEU1 and A. ureafaciens neuramidase were constructed by 
multitemplate modeling using Phyre2 protein fold recognition software (Kelley et al. 2015) 
based on the X-ray diffraction crystal structure of NEU2 (National Center for Biotechnology 
Information, Bethesda, MD, Protein Database ID #1VCU) (Chavas et al. 2005). C9-BA-DANA 
was docked onto the NEU1 structure using AutoDock Vina software (Trott and Olson 2010), 
resulting in a model similar to that previously described by Magesh et al. (2006, 2008). X-ray 
structures for V. cholerae (Protein Database ID #1W0O) (Moustafo et al. 2004) and C. 
perfringens NanI (Protein Database ID #2VK6) (Newstead et al. 2008) neuraminidases and the 
model of A. ureafaciens neuraminidase were superimposed onto the C9-BA-DANA–NEU1 
model using the structural alignment algorithm in UCSF Chimera (Petterson et al. 2004) or the 
cealign command in PyMOL (version 1.3, Schrodinger, LLC, Cambridge, MA). Amino acid 
sequence alignments of the β7–β8 loop of NEU1, -2, -3 and -4 and the three bacterial 
neuraminidases were created using PROMALS3D (Pei et al. 2008) and, in the case of C. 
perfringens NanI, adjusted based on the structural alignment with NEU1 to account for the 
insertion domain beginning after the β7 strand. 
C9-BA-DANA inhibition of flagellin-induced increases in total sialidase activity 
in mouse lungs 
All animal experiments were approved by the University of Maryland Baltimore Institutional 
Animal Use and Care Committee. Female BALB/c mice (18–20 g) were obtained from Charles 
River Laboratories (Frederick, MD). The mice were intraperitoneally injected with 15 mg/kg of 
C9-BA-DANA or DANA dissolved in 25 µL of nonpyrogenic normal saline or saline alone. 
After 24 h, mice were intranasally administered flagellin (100 ng/mouse) or the PBS vehicle 
alone. At 4 h, the mice were euthanized by CO2 inhalation and cervical dislocation, and the lungs 
and kidneys were harvested, weighed and transferred to tubes on ice containing PBS and a 
protease inhibitor cocktail (Sigma), and homogenized at 4°C. Lung and kidney homogenates 
were centrifuged at 14,000 × g for 10 min at 4°C and supernates were processed for total protein 
levels and total sialidase activity for the 4-MU-NANA substrate. 
Statistical methods 
All values were expressed as mean ± SE. Differences between means were compared using the 
Student's t-test or ANOVA followed by the Tukey's multiple range test and considered 
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aeruginosa; PBS-T, PBS containing 0.05% Tween-20; PNA, peanut agglutinin; PPCA, 
protective protein/cathepsin A; PVDF, polyvinylidene fluoride; SAEC, small airway epithelial 
cell; TLR, Toll-like receptor. 
 
References 
1. Abdulkhalek S, Amith SR, Franchuk SL, Jayanth P, Guo M, Finlay T, Gilmour A, Guzzo 
C, Gee K, Beyaert R, et al. . 2011. Neu1 sialidase and matrix metalloproteinase-9 cross-
talk is essential for Toll-like receptor activation and cellular signaling. J Biol Chem. 
286:36532–36549. [PMC free article] [PubMed] [Google Scholar] 
2. Abdulkhalek S, Guo M, Amit SR, Jayanth P, Szewczuk MR. 2012. G-protein coupled 
receptor agonists mediate Neu1 sialidase and matrix metalloproteinase-9 cross-talk to 
induce transactivation of TOLL-like receptors and cellular signaling. Cell Signal. 
24:2035–2042. [PubMed] [Google Scholar] 
3. Abdulkhalek S, Szewczuk MR. 2013. Neu1 sialidase and matrix metalloproteinase-9 
cross-talk regulates nucleic acid-induced endosomal TOLL-like receptor-7 and -9 
activation, cellular signaling and pro-inflammatory responses. Cell Signal. 25:2093–
2105. [PubMed] [Google Scholar] 
4. Albohy A, Zhang Y, Smutova V, Pshezhetsky AV, Cairo CW. 2013. Identification of 
selective nanomolar inhibitors of the human neuraminidase, NEU4. ACS Med Chem 
Lett. 4:532–537. [PMC free article] [PubMed] [Google Scholar] 
5. Amith SR, Jayanth P, Franchuk S, Finlay T, Seyrantepe V, Beyaert R, Pshezhetsky AV, 
Szewczuk MR. 2010. Neu1 desialylation of sialyl α-2,3-linked β-galactosyl residues of 
TOLL-like receptor 4 is essential for receptor activation and cellular signaling. Cell 
Signal. 22:314–324. [PubMed] [Google Scholar] 
6. Amith SR, Jayanth P, Franchuk S, Siddiqui S, Seyrantepe V, Gee K, Basta S, Beyaert R, 
Pshezhetsky AV, Szewczuk MR. 2009. Dependence of pathogen molecule-induced Toll-
like receptor activation and cell formation on Neu1 sialidase. Glycoconj J. 26:1197–1212. 
[PubMed] [Google Scholar] 
7. Arabkhari M, Bunda S, Wang Y, Wang A, Pshezhetsky AV, Hinek A. 2010. 
Desialylation of insulin receptors and IGF-1 receptors by neuraminidase-1 controls the 
net proliferative response of L6 myoblasts to insulin. Glycobiology. 20:603–616. 
[PubMed] [Google Scholar] 
8. Bonten E, van der Spoel A, Fornerod M, Grosveld G, d'Azzo A. 1996. Characterization 
of human lysosomal neuraminidase defines the molecular basis of the metabolic storage 
disorder sialidosis. Genes Dev. 10:3156–3169. [PubMed] [Google Scholar] 
9. Burmeister WP, Henrissat B, Bosso C, Cusack S, Ruigrok RW. 1993. Influenza B virus 
neuraminidase can synthesize its own inhibitor. Structure. 1:19–26. [PubMed] [Google 
Scholar] 
10. Chavas LMG, Tringali C, Fusi P, Venerando B, Tettamanti G, Kato R, Monti E, 
Wakatsuki S. 2005. Crystal structure of the human cytosolic sialidase Neu2. Evidence for 
the dynamic nature of substrate recognition. J Biol Chem. 280:469–475. [PubMed] 
[Google Scholar] 
11. Chen G, Chen X, King S, Cavassani KA, Cheng J, Zheng X, Cao H, Yu H, Qu J, Fang D, 
et al. . 2011. Amelioration of sepsis by inhibiting sialidase-mediated disruption of the 
CD24-SiglecG interaction. Nat Biotechnol. 29:428–435. [PMC free article] [PubMed] 
[Google Scholar] 
12. Cohen M, Varki A. 2010. The sialome-Far more than the sum of its parts. OMICS. 
14:455–464. [PubMed] [Google Scholar] 
13. Comelli EM, Amado M, Lustig SR, Paulson JC. 2003. Identification and expression of 
Neu4, a novel murine sialidase. Gene. 321:155–161. [PubMed] [Google Scholar] 
14. Cross AS, Hyun SW, Miranda-Rivera A, Feng C, Liu A, Nguyen C, Zhang L, Luzina IG, 
Atamas SP, Twaddell WS, et al. . 2012. NEU1 and NEU3 sialidase activity expressed in 
human lung microvascular endothelia. NEU1 restrains endothelial cell migration whereas 
NEU3 does not. J Biol Chem. 287:15966–15980. [PMC free article] [PubMed] [Google 
Scholar] 
15. Cross AS, Sakarya S, Rifat S, Held TK, Drysdale B, Grange PA, Cassels FJ, Wang L, 
Stamatos N, Farese A, et al. . 2003. Recruitment of murine neutrophils in vivo through 
endogenous sialidase activity. J Biol Chem. 278:4112–4120. [PubMed] [Google Scholar] 
16. Cuniberti LA, Martinez V, Schachter J, Magarinos G, Meckert PC, Laguens RP, 
Levenson J, Werba JP. 2005. Sialic acid as a protective barrier against neointima 
development. Atherosclerosis. 181:225–231. [PubMed] [Google Scholar] 
17. de Geest N, Bonten E, Mann L, de Sousa-Hitzler J, Hahn C, d'Azzo A. 2002. Systemic 
and neurologic abnormalities distinguish the lysosomal disorders sialidosis and 
galactosialidosis in mice. Hum Mol Genet. 11:1455–464. [PubMed] [Google Scholar] 
18. Dridi L, Seyrantepe V, Fougerat A, Pan X, Bonneil E, Thibault P, Moreau A, Mitchell 
GA, Heveker N, Cairo CW, et al. . 2013. Positive regulation of insulin signaling by 
neuraminidase 1. Diabetes. 62:2338–2346. [PMC free article] [PubMed] [Google 
Scholar] 
19. Duca L, Blanchevoye C, Cantarelli B, Ghoneim C, Dedieu S, Delacoux F, Hornebeck W, 
Hinek A, Martiny L, Debelle L. 2007. The elastin receptor complex transduces signals 
through the catalytic activity of it's Neu-1 subunit. J Biol Chem. 282:12484–12491. 
[PubMed] [Google Scholar] 
20. Fanzani A, Guiliani R, Colombo F, Zizioloi D, Presta M, Preti A, Marchesini S. 2003. 
Overexpression of cytosolic sialidase Neu2 induces myoblast differentiation in C2C12 
cells. FEBS Lett. 547:183–188. [PubMed] [Google Scholar] 
21. Feng C, Stamatos NM, Dragan AI, Medvedev A, Whitford M, Zhang L, Song C, 
Rallabhandi P, Cole L, Nhu QM, et al. .. 2012. Sialyl residues modulate LPS-mediated 
signaling through the Toll-like receptor 4 complex. PLoS One. 7:e32359. [PMC free 
article] [PubMed] [Google Scholar] 
22. Feng C, Zhang L, Nguyen C, Vogel SN, Goldblum SE, Blackwelder WC, Cross AS. 
2013. Neuraminidase reprograms lung tissue and potentiates lipopolysaccharide-induced 
acute lung injury in mice. J Immunol. 191:4828–4837. [PMC free article] [PubMed] 
[Google Scholar] 
23. Fontenot JD, Mariappan SV, Castasti P, Domenech N, Finn OJ, Gupta G. 1995. Structure 
of a tumor associated antigen containing a tandemly repeated immunodominant epitope. J 
Biol Struct Dyn. 13:245–260. [PubMed] [Google Scholar] 
24. Gayral S, Garnotel R, Castaing-Berthou A, Blaise S, Fougerat A, Berge E, Montheil A, 
Malet N, Wymann MP, Maurice P, et al. . 2014. Elastin-derived peptides potentiate 
atherosclerosis through the immune NEU-1 P13K gamma pathway. Cardiovasc Res. 
102:118–127. [PubMed] [Google Scholar] 
25. Golovanova NK, Gracheva EV, Il'inskaya OP, Tararak EM, Prokazova NV. 2002. 
Sialidase activity in normal and atherosclerotic aortic intima. Biochemistry (Moscow). 
67:1490–1495. [PubMed] [Google Scholar] 
26. Gopaul KP, Crook MA. 2006. Sialic acid: A novel marker of cardiovascular disease. Clin 
Biochem. 39:667–681. [PubMed] [Google Scholar] 
27. Grewal PK, Uchiyama S, Ditta D, Varki N, Le DT, Nizet V, Marth JD. 2008. The 
Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med. 14:648–655. 
[PMC free article] [PubMed] [Google Scholar] 
28. Hata K, Koseki K, Yamaguchi K, Moriya S, Suzuki Y, Yingsakmongkon S, Hirai G, 
Sodeoka M, von Itzstein M, Miyagi T. 2008. Limited inhibitory effects of osteltamivir 
and zanamivir on human sialidases. Antimicrob Agents Chemother. 52:3484–3491. 
[PMC free article] [PubMed] [Google Scholar] 
29. Hinek A, Bodaruk TD, Bunda S, Wang Y, Liu K. 2008. Neuraminidase-1, a subunit of 
the cell surface elastin receptor, desialylates and functionally inactivates adjacent 
receptors interacting with the mitogenic growth factors PDGF-BB and IGF-2. Am J 
Pathol. 173:1042–1056. [PMC free article] [PubMed] [Google Scholar] 
30. Hinek A, Pshezhetsky A, von Itzstein M, Starcher B. 2006. Lysosomal sialidase 
(neuraminidase-1) is targeted to the cell surface in a multiprotein complex that facilitates 
elastic fiber assembly. J Biol Chem. 281:3698–3710. [PubMed] [Google Scholar] 
31. Igdoura SA, Gafuik C, Mertineit C, Saberi F, Pschezhetsky AV, Potier M, Trasler JM, 
Gravel RA. 1998. Cloning of the cDNA and gene encoding mouse lysosomal sialidase 
and correction of sialidase deficiency in human sialdosis and mouse SM/J fibroblasts. 
Hum Mol Genet. 7:115–121. [PubMed] [Google Scholar] 
32. Kappagantula S, Andrews MR, Cheah M, Abad-Rodriguez J, Dotti CG. 2014. Neu3 
sialidase-mediated ganglioside consersion is necessary for axon regeneration and is 
blocked in CNS axons. J Neurosci. 34:2477–2492. [PMC free article] [PubMed] [Google 
Scholar] 
33. Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJ. 2015. The Phyre2 web portal 
for protein modeling, prediction and analysis. Nat Protoc. 10:845–858. [PMC free article] 
[PubMed] [Google Scholar] 
34. Kim S, Oh D, Kang H, Kwon O. 2011. Features and applications of bacterial sialidases. 
Appl Microbiol Biotechnol. 91:1–15. [PubMed] [Google Scholar] 
35. Kiyohara M, Tanigawa K, Chaiwangsr T, Katayama T, Ashida H, Yamamoto K. 2011. 
An exo-a-sialidase from bifidobacteria involved in the degradation of 
sialyloligosaccharides in human milk and intestinal glycoconjugates. Glycobiology. 
21:437–447. [PubMed] [Google Scholar] 
36. Lee C, Liu A, Miranda-Ribera A, Hyun SW, Lillehoj EP, Cross AS, Passaniti A, Grimm 
PR, Kim B, Welling PA, et al. . 2014. NEU1 sialidase regulates the sialylation state of 
CD31 and disrupts CD31-driven capillary-like tube formation in the human lung 
microvascular endothelia. J Biol Chem. 289:9121–9135. [PMC free article] [PubMed] 
[Google Scholar] 
37. Lewis AL, Lewis WG. 2012. Host sialoglycans and bacterial sialidases: A mucosal 
perspective. Cell Microbiol. 14:1174–1182. [PubMed] [Google Scholar] 
38. Lillehoj EP, Hyun SW, Feng C, Zhang L, Liu A, Guang W, Nguyen C, Luzina IG, 
Atamas SP, Passaniti A, et al. . 2012. NEU1 sialidase expressed in human airway 
epithelia regulates epidermal growth factor receptor and MUC1 signaling. J Biol Chem. 
287:8214–8231. [PMC free article] [PubMed] [Google Scholar] 
39. Lillehoj EP, Hyun SW, Guang W, Liu A, Verceles AC, Luzina IG, Atamas SP, Kim KC, 
Goldblum SE. 2015. NEU1 sialidase regulates membrane-tethered mucin (MUC1) 
ectodomain adhesiveness for Pseudomonas aeruginosa and decoy receptor release. J Biol 
Chem. 290:18316–18331. [PMC free article] [PubMed] [Google Scholar] 
40. Lillehoj EP, Kato K, Lu W, Kim KC. 2013. Cellular and molecular biology of airway 
mucins. Int Rev Cell Mol Biol. 303:139–202. [PMC free article] [PubMed] [Google 
Scholar] 
41. Luzina IG, Lockatell V, Hyun SW, Kopach P, Kang PH, Noor Z, Liu A, Lillehoj EP, Lee 
C, Miranda-Ribera A, et al. . 2016. Elevated expression of NEU1 sialidase in idiopathic 
pulmonary fibrosis provokes pulmonary collagen deposition, lymphocytosis, and fibrosis. 
Am J Physiol Lung Cell Mol Physiol. 310:L940–L954. [PMC free article] [PubMed] 
[Google Scholar] 
42. Ma F, Wu D, Deng L, Secrest P, Zhao J, Varki N, Lindheim S, Gagneax P. 2012. 
Sialidases on mammalian sperm mediate deciduous sialylation during capacitation. J Biol 
Chem. 287:38073–38079. [PMC free article] [PubMed] [Google Scholar] 
43. Magesh S, Moriya S, Suzuki T, Miyagi T, Ishida H, Kiso M. 2008. Design, synthesis, and 
biological evaluation of human sialidase inhibitors. Part 1: Selective inhibitors of 
lysosomal sialidase (NEU1). Bioorg Med Chem Lett. 18:532–537. [PubMed] [Google 
Scholar] 
44. Magesh S, Savita V, Moriya S, Suzuki T, Miyagi T, Ishida H, Kiso M. 2009. Human 
sialidase inhibitors: Design, synthesis, and biological evaluation of 4-acetamido-5-
acylamido-2-fluoro benzoic acids. Bioorg Med Chem. 17:4595–4603. [PubMed] [Google 
Scholar] 
45. Magesh S, Suzuki T, Miyagi T, Ishida H, Kiso M. 2006. Homology modeling of human 
sialidase enzymes NEU1, NEU3, and NEU 4 based on the crystal structure of NEU2: 
Hints for the design of selective NEU3 inhibitors. J Mol Graph Model. 25:196–207. 
[PubMed] [Google Scholar] 
46. Meindi P, Tuppy H. 1969. 2-Deoxy-2, 3-dehydrosialic acids. II. Competitive inhibition of 
Vibrio cholerae neuraminidases by 2-deoxy-2, 3-dehydro-N-acylneuraminic acids. 
Hoppe Seylers Z Physiol Chem. 350:1088–1092. [PubMed] [Google Scholar] 
47. Miyagi T, Wada T, Iwamatsu A, Hata K, Yoshikawa Y, Tokuyama S, Sawada M. 1999. 
Molecular cloning and characterization of a plasma membrane-associated sialidase 
specific for gangliosides. J Biol Chem. 274:5004–5011. [PubMed] [Google Scholar] 
48. Miyagi T, Wada T, Yamaguchi K. 2008. Roles of plasma membrane-associated sialidase 
NEU3 in human cancers. Biochim Biophys Acta. 1780:532–537. [PubMed] [Google 
Scholar] 
49. Miyagi T, Wada T, Yamaguchi K, Hata K. 2004. Sialidase and malignancy: A 
minireview. Glycoconj J. 20:189–198. [PubMed] [Google Scholar] 
50. Miyagi T, Yamaguchi K. 2012. Mammalian sialidases: Physiological and pathological 
roles in cellular functions. Glycobiology. 22:880–896. [PubMed] [Google Scholar] 
51. Mochizuki S, Brassart B, Hinek A. 2002. Signaling pathways transduced through the 
elastin receptor facilitate proliferation of arterial smooth muscle cells. J Biol Chem. 
277:44854–44863. [PubMed] [Google Scholar] 
52. Monti E, Bonten E, D'Azzo A, Bresciani R, Venerando B, Borsani G, Schauer R, 
Tettamanti G. 2010. Sialidases in vertebrates: A family of enzymes tailored for several 
cell functions. Adv Carbohydr Chem Biochem. 64:403–479. [PubMed] [Google Scholar] 
53. Monti E, Preti A, Nesti C, Ballabio A, Borsani G. 1999. Expression of a novel human 
sialidase encoded by the NEU2 gene. Glycobiology. 9:1313–1321. [PubMed] [Google 
Scholar] 
54. Monti E, Preti A, Venerando B, Borsani G. 2002. Recent development in mammalian 
sialidase molecular biology. Neurochem Res. 27:649–663. [PubMed] [Google Scholar] 
55. Moustafo I, Connaris H, Taylor M, Zaitsev V, Wilson JC, Kiefel MJ, von Itzstein M, 
Taylor GL. 2004. Sialic acid recognition by Vibrio cholerae neuraminidase. J Biol Chem. 
279:40819–40826. [PubMed] [Google Scholar] 
56. Nacu N, Luzina IG, Highsmith K, Lockatell V, Pochetuhen K, Cooper ZA, Gillmeister 
MP, Todd NW, Atamas SP. 2008. Macropages produce TGF-β-induced (β-ig-h3) 
following ingestion of apoptotic cells and regulate MMP14 levels and collagen turn over 
in fibroblasts. J Immunol. 180:5036–5044. [PMC free article] [PubMed] [Google 
Scholar] 
57. Newstead SL, Potter JA, Wilson JC, Xu G, Chien CH, Watts AG, Withers SG, Taylor 
GL. 2008. The structure of Clostridium perfringens NanI sialidase and its catalytic 
intermediates. J Biol Chem. 283:9090–9098. [PMC free article] [PubMed] [Google 
Scholar] 
58. Parry S, Silverman HS, McDermott K, Willis A, Hollingsworth MA, Harris A. 2001. 
Identification of MUC1 proteolytic cleavage sites in vivo. Biochem Biophys Res 
Commun. 283:715–720. [PubMed] [Google Scholar] 
59. Pei J, Kim BH, Grishin NV. 2008. PROMALS3D: A tool for multiple protein sequence 
and structure alignments. Nucleic Acids Res. 36:2295–2300. [PMC free article] 
[PubMed] [Google Scholar] 
60. Petterson EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. 
2004. UCSF Chimera-a visualization system for exploratory research and analysis. J 
Comput Chem. 25:1605–1612. [PubMed] [Google Scholar] 
61. Pshezhetsky AV, Richard C, Michaud L, Igdoura S, Wang S, Elsliger MA, Qu J, Leclerc 
D, Gravel R, Dallaire L, et al. . 1997. Cloning, expression and chromosomal mapping of 
human lysosomal sialidase and characterization of mutations in sialidosis. Nat Genet. 
15:316–320. [PubMed] [Google Scholar] 
62. Seyrantepe V, Iannello A, Liang F, Kanshin E, Jayanth P, Samarani S, Szewczuk MR, 
Ahmad A, Pshezhetsky AV. 2010. Regulation of phagocytosis in macrophages by 
neuraminidase I. J Biol Chem. 285:206–215. [PMC free article] [PubMed] [Google 
Scholar] 
63. Smutova V, Albohy A, Pan X, Korchagina E, Miyagi T, Bovin N, Cairo CW, 
Pshezhetsky AV. 2014. Structural basis for substrate specificity of mammalian 
neuraminidases. PLoS One. 9:e106320. [PMC free article] [PubMed] [Google Scholar] 
64. Starcher B, d'Azzo A, Keller PW, Rao GK, Nadarajah D, Hinek A. 2008. Neuraminidase-
1 is required for the normal assembly of elastic fibers. Am J Physiol Lung Cell Mol 
Physiol. 295:L637–L647. [PMC free article] [PubMed] [Google Scholar] 
65. Tertov VV, Kaplun VV, Sobenin IA, Orekhov AN. 1998. Low-density lipoprotein 
modification occurring in human plasma. Possible mechanism of in vivo lipoprotein 
desialylation as a primary step of atherogenic modification. Atherosclerosis. 138:183–
195. [PubMed] [Google Scholar] 
66. Trott O, Olson AJ. 2010. AutoDock, Vina: Improving the speed and accuracy of docking 
with a new scoring function, efficient organization, and multithreading. J Comput Chem. 
31:455–461. [PMC free article] [PubMed] [Google Scholar] 
67. Uemura T, Shiozaki K, Yamaguchi K, Miyazaki S, Satomi S, Kato K, Sakuraba H, 
Miyagi T. 2009. Contribution of sialidase NEU1 to suppression of metastasis of human 
colon cancer cells through desialylation of integrin β4. Oncogene. 28:1218–1229. 
[PubMed] [Google Scholar] 
68. Varki NM, Varki A. 2007. Diversity in cell surface sialic acid presentations: Implications 
for biology and disease. Lab Invest. 87:851–857. [PMC free article] [PubMed] [Google 
Scholar] 
69. von Itzstein M. 2007. The war against influenza: Discovery and development of sialidase 
inhibitors. Nat Rev Drug Discov. 6:967–974. [PubMed] [Google Scholar] 
70. Wada T, Yoshikawa Y, Tokuyama S, Kuwabara M, Akita H, Miyagi T. 1999. Cloning, 
expression, and chromosomal mapping of a human ganglioside sialidase. Biochem 
Biophys Res Commun. 261:21–27. [PubMed] [Google Scholar] 
71. Zhang Y, Albohy A, Zou Y, Smutova V, Pshezhetsky AV, Cairo CW. 2013Identification 
of selective inhibitors of human neuraminidase isoenzymes using C4,C7-modified 2-
deoxy-2,3-didehydro-N-acetylneuraminic acid (DANA) analougues. J Med Chem. 
56:2948–2958. [PubMed] [Google Scholar] 
 
Articles from Glycobiology are provided here courtesy of Oxford University Press 
 
 
